One, two, three steps toward cell therapy for stroke

Stroke

Volumn 46, Issue 2, 2015, Pages 588-591

  Diamandis, Theo ^a   Borlongan, Cesar V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

standards; stem cells; stroke; therapy

Indexed keywords

CELL PROLIFERATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; FOOD AND DRUG ADMINISTRATION; HOST CELL; HUMAN; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NOTE; PRIORITY JOURNAL; SAFETY; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; THERAPY EFFECT; ANIMAL; BIOLOGICAL THERAPY; PRACTICE GUIDELINE; STANDARDS; STROKE; TRENDS;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC; STEM CELL TRANSPLANTATION; STROKE;

EID: 84922336600     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007105     Document Type: Note

References (29)

1. Tajiri N, Dailey T, Metcalf C, Mosley YI, Lau T, Staples M, et al. In vivo animal stroke models: a rationale for rodent and non-human primate models. Transl Stroke Res. 2013;4:308-321. doi: 10.1007/s12975-012-0241-2.
2. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother. 2008;8:1193-1201. doi: 10.1586/14737175.8.8.1193.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
4. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol. 2011;95:213-228. doi: 10.1016/j.pneurobio.2011.08.005.
5. Tan Tanny SP, Busija L, Liew D, Teo S, Davis SM, Yan B. Costeffectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center. Stroke. 2013;44:2269-2274. doi: 10.1161/STROKEAHA.113.001295.
6. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309:2480-2488. doi: 10.1001/jama.2013.6959.
7. Fisher M, Albers GW. Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Ann Neurol. 2013;73:4-9. doi: 10.1002/ana.23744.
8. Chopp M, Steinberg GK, Kondziolka D, Lu M, Bliss TM, Li Y, et al. Who's in favor of translational cell therapy for stroke: STEPS forward please? Cell Transplant. 2009;18:691-693. doi: 10.3727/096368909X470883.
9. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009;40: 510-515.
10. Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell Prolif. 2008;41(suppl 1):94-114. doi: 10.1111/j.1365-2184.2008.00486.x.
11. Borlongan CV, Chopp M, Steinberg GK, Bliss TM, Li Y, Lu M, et al. Potential of stem/progenitor cells in treating stroke: the missing steps in translating cell therapy from laboratory to clinic. Regen Med. 2008;3:249-250. doi: 10.2217/17460751.3.3.249.
12. Borlongan CV, Tajima Y, Trojanowski JQ, Lee VM, Sanberg PR. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol. 1998;149:310-321. doi: 10.1006/exnr.1997.6730.
13. Nelson PT, Kondziolka D, Wechsler L, Goldstein S, Gebel J, DeCesare S, et al. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. Am J Pathol. 2002;160:1201-1206. doi: 10.1016/S0002-9440(10)62546-1.
14. Stroemer P, Patel S, Hope A, Oliveira C, Pollock K, Sinden J. The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion. Neurorehabil Neural Repair. 2009;23:895-909. doi: 10.1177/1545968309335978.
15. Sinden JD, Vishnubhatla I, Muir KW. Prospects for stem cell-derived therapy in stroke. Prog Brain Res. 2012;201:119-167. doi: 10.1016/B978-0-444-59544-7.00007-X.
16. Teng YD, Benn SC, Kalkanis SN, Shefner JM, Onario RC, Cheng B, et al. Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med. 2012;4:165ra164. doi: 10.1126/scitranslmed.3004579.
17. Teng YD, Yu D, Ropper AE, Li J, Kabatas S, Wakeman DR, et al. Functional multipotency of stem cells: a conceptual review of neurotrophic factor-based evidence and its role in translational research. Curr Neuropharmacol. 2011;9:574-585. doi: 10.2174/157015911798376299.
18. STAIR Consensus Conferences: Introduction. Stroke Treatment Academic Industry Roundtable Web site. http://www.thestair.org/. Accessed August 11, 2014.
19. Stroke Therapy Acadmic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.
20. Savitz S, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L, et al. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) II. Stroke. 2011;42:825-829.
21. Savitz S, Cramer C, Wechsler L on behalf of STEPS 3 Consortium. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke. 2014;45:634-639.
22. Glover LE, Tajiri N, Weinbren NL, Ishikawa H, Shinozuka K, Kaneko Y, et al. A step-up approach for cell therapy in stroke: translational hurdles of bone marrow-derived stem cells. Transl Stroke Res. 2012;3:90-98. doi: 10.1007/s12975-011-0127-8.
23. Chopp M, Zhang ZG, Jiang Q. Neurogenesis, angiogenesis, and MRI indices of functional recovery from stroke. Stroke. 2007;38:827-831.
24. Guzman R, Uchida N, Bliss TM, He D, Christopherson KK, Stellwagen D, et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci U S A. 2007;104:10211-10216. doi: 10.1073/pnas.0608519104.
25. Hara K, Matsukawa N, Yasuhara T, Xu L, Yu G, Maki M, et al. Transplantation of post-mitotic human neuroteratocarcinoma-overexpressing Nurr1 cells provides therapeutic benefits in experimental stroke: in vitro evidence of expedited neuronal differentiation and GDNF secretion. J Neurosci Res. 2007;85:1240-1251. doi: 10.1002/jnr.21234.
26. Janowski M, Walczak P, Date I. Intravenous route of cell delivery for treatment of neurological disorders: a meta-analysis of preclinical results. Stem Cells Dev. 2009;19:5-16.
27. Seminatore C, Polentes J, Ellman D, Kozubenko N, Itier V, Tine S, et al. The postischemic environment differentially impacts teratoma or tumor formation after transplantation of human embryonic stem cellderived neural progenitors. Stroke. 2010;41:153-159. doi: 10.1161/STROKEAHA.109.563015.
28. Hicks AU, Hewlett K, Windle V, Chernenko G, Ploughman M, Jolkkonen J, et al. Enriched environment enhances transplanted subventricular zone stem cell migration and functional recovery after stroke. Neuroscience. 2007;146:31-40. doi: 10.1016/j.neuroscience.2007.01.020.
29. Borlongan CV, Weiss MD. Baby STEPS: a giant leap for cell therapy in neonatal brain injury. Pediatr Res. 2011;70:3-9. doi: 10.1203/PDR.0b013e31821d0d00.